European Psychiatry - Volume 33 - March 2016

377 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S373
Objective Zolpidem is a non-benzodiazepine hypnotic drug for
treatment of insomnia and is generally believed that is a safe medi-
cation. Therefore has been introduced as a lower potential agent for
dependency and abusive effects however its safety and dependence
potential are of great concern.
Case report A 63 years old male patient had consulted a general
physician in January 2015 for his insomnia. He started on zolpi-
dem 10mg at bedtime. Over the next fewmonths he had gradually
increased the dose as he found the prescribed dose to be hav-
ing no significant effect. After abrupt discontinuation of zolpidem,
he presented to a center for drug users “AIDE ET ECOUTE” with
severe anxiety, impatience, loss of energy, insomnia, irritability,
headaches, and increased craving for higher dosage of zolpidem.
There was no history of any other substance abuse and he was diag-
nosed simultaneously a case of zolpidem dependence and major
depressive disorder.
Conclusions Zolpidem has a potency to be abused with high
risk of dependency and withdrawal syndromes particularly among
elderly patients with comorbid anxiety and depressive disorders.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV72
Nalmefene as an intermittent
treatment for alcohol abuse triggering
cocaine and sex consumption
A. Morera-Fumero ∗, E. Diaz-Mesa
1 University of La Laguna, Internal Medicine – Dermatology and
Psychiatry, Santa Cruz de Tenerife, Spain
2 Psychiatric Consulting, Psychiatry, Santa Cruz de Tenerife, Spain
3 University Hospital of the Canary Islands, Psychiatry, La Laguna,
Spain
∗ Corresponding author.
Nalmefene modulates the motivational system by blocking the
opioids receptors. Nalmefene indication is the alcohol consump-
tion reduction in alcoho dependent patients. We describe the case
of a patient with weekend alcohol abuse that was followed by
cocaine use and sex. After being treatedwith nalmefene, the patient
decreased alcohol consumption and did not engage cocaine use
and sex. The patient is a 36-year-old man with a previous his-
tory of cocaine, cannabis and alcohol abuse. After detoxification
the patient became aweekend drinker. Twomonths later he started
complaining that after drinking he needed to consume cocaine and
this led him to having sex with prostitutes. These behaviours had
a serious impact on his finances that lead him to asking for help.
Nalmefene, 18mg at dinner before going out, was prescribed. Tak-
ing one pill of nalmefene “allowedme to drink several shotswithout
feeling a need to continue drinking and, most importantly, I didn’t
feel the need to consume cocaine and have sex”. In an attempt to
ascertain if what had happened the previous weekend was “psy-
chological” the patient went out without taking nalmefene. The
pattern of alcohol use, control loss, and consumption of cocaine and
sex repeated itself. During the following two months, the patient
took nalmefene during dinner before going out every weekend and
the results were the same as when he first took the treatment.
Conclusion Nalmefene may be helpful in the treatment of sev-
eral other addictions by blocking the positive reinforcements of
the drugs.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV73
A case of share psychotic disorder
induced by mephedrone
R.A. Baena∗, Y. Lázaro , J. Rodriguez , L. Olivares , A. Matas ,
L. Niell
Hospital Clinico San Carlos, Psychyatry, Madrid, Spain
∗ Corresponding author.
Introduction Share psychotic disorder “folie à deux” is a rare con-
dition characterized by the transmission of delusional aspects from
a patient to another linked by a close relationship. We report the
case of two Spanish men who have experienced a combined delu-
sional episode induced by mephedrone.
Objectives Describe a case of share psychotic disorder induced by
mephedrone. Make a review on scientific literature about the use
of mephedrone (little is known about the psychiatric consequences
of the use of these compounds). The patients had no psychiatric
history.
Aims Show the danger of these novel drugs that are often bought
as apparently safe and legal.
Conclusions Share psychotic disorder was first introduced by
Lasegue and Falret who hypothesized that transmission of psychi-
atric disturbance from one person to another was possible under
certain circumstances. The correlation of symptoms with the intake
of these substances is supposed in the light of a negative psychi-
atric history and no other concomitant medical treatments. An
important number of case reports documented deaths related to
the ingestion of mephedrone. Another problem is that these sub-
stances are not detected by standard blood and urine test so that
the diagnosis of intoxication is often delayed.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV74
The experience of using synthetic
cannabinoids: A qualitative analysis of
online user self-reports
M. Newman ∗, G. Denton , T. Walker , J. Grewal
1 University of Warwick, Warwick Medical School, Coventry, United
Kingdom
2 Caludon centre, Addiction Psychiatry, Coventry, United Kingdom
∗ Corresponding author.
Introduction The number of novel psychoactive substances (NPS)
available is increasing. Synthetic cannabinoids (SC) are one of many
NPS sold. SC aim to emulate the effects of natural cannabis by acting
on cannabinoid receptors. Despite much research into pharmacol-
ogy, there is limited data on the user experience of SC.
Aim It is useful for psychiatrists, to understand what experiences
people have whilst on illicit substances. The aim of this qualitative
study is to gain an initial understanding of what characterizes the
experiences of those who use SC.
Method Fourty anonymously written online reports were col-
lected from the “Erowid experience vaults” and analysed using the
Empirical Phenomenological Psychological Method.
Results The analysis yielded 488meaning units (MU). Thesewere
grouped into 36 categories revealing 5 broad themes: (1) physical
affects; (2) sensory distortions and distortions of perception; (3)
emotional and psychological effects; (4) re-dosing, addiction and
comedown effects; (5) similarities to other substances.
Conclusion Synthetic cannabinoids have a mixed effect on users
with a myriad of experiences reported. Some experienced positive
results from their usage such as euphoria and relaxation, however
these were counter balanced by those who experienced some seri-
ous negative emotional and physical side effects such as anxiety,
paranoia, palpitations and convulsions. SC appear to often emulate
that of their natural counterpart, yet there is an unpredictability